Table 1.
Baseline Characteristics of the Participants
| MESA Lung (N = 2,517) | SPIROMICS (N = 2,339) |
||
|---|---|---|---|
| Control Subjects (n = 781) | Cases (n = 1,558) | ||
| Genetic risk score, mean (SD) | 87.3 (6.6) | 88.0 (6.6) | 88.7 (6.5) |
| Age, mean (SD), yr | 69.1 (9.3) | 60.5 (9.6) | 65.3 (8.0) |
| Height, mean (SD), cm | 165.4 (9.9) | 169.5 (9.3) | 170.2 (9.6) |
| Body mass index, mean (SD), kg/m2 | 28.4 (5.5) | 29.0 (5.1) | 27.3 (5.3) |
| Male, n (%) | 1,206 (47.9) | 374 (47.9) | 894 (57.4) |
| Race/ethnicity, n (%) | |||
| Non-Hispanic white | 995 (39.5) | 557 (71.3) | 1,292 (82.9) |
| African American | 617 (24.5) | 206 (26.4) | 238 (15.3) |
| Hispanic/Latino | 551 (21.9) | 0 (0) | 0 (0) |
| Asian American | 354 (14.1) | 4 (0.5) | 19 (1.2) |
| Smoking status, n (%) | |||
| Never | 1,228 (48.8) | 0 (0) | 0 (0) |
| Former | 1,126 (44.7) | 382 (48.9) | 1,018 (65.3) |
| Current | 163 (6.5) | 399 (51.1) | 540 (34.7) |
| Pack-years, median (Q1–Q3)* | 12 (2–30) | 37.5 (30.0–49.5) | 47.0 (35.0–63.0) |
| Lung function | |||
| FEV1, mean (SD), percent predicted† | 95.5 (23.0) | 90.8 (14.3) | 53.9 (22.4) |
| FEV1/FVC, mean (SD), percent | 74.1 (8.8) | 74.0 (5.5) | 49.7 (12.9) |
| COPD, n (%) | |||
| GOLD 1 | 89 (4.2) | 11 (1.4) | 340 (21.9) |
| GOLD 2 | 62 (2.9) | 9 (1.2) | 699 (44.9) |
| GOLD 3 | 9 (0.4) | 0 (0) | 363 (23.3) |
| GOLD 4 | 8 (0.4) | 0 (0) | 148 (9.5) |
| Lung structure | |||
| Lung density | |||
| Percent emphysema, median (Q1–Q3), percent | 1.44 (0.58–3.02) | 0.98 (0.47–2.06) | 6.70 (2.34–15.46) |
| Percent emphysema > ULN, n (%) | 207 (8.2) | 59 (7.6) | 836 (53.7) |
| PRMfSAD, median (Q1–Q3), percent | 6.0 (2.0–11.0) | 27.0 (16.0–37.0) | |
| Airway dimensions | |||
| Inner airway diameter, median (Q1–Q3), mm | 4.3 (3.6–5.0) | 4.4 (3.1–6.2) | 4.1 (2.7–5.9) |
| Average wall area, median (Q1–Q3), mm2 | 30.3 (24.2–37.1) | 51.7 (29.1–87.9) | 47.3 (25.2–82.6) |
| Percent wall area, median (Q1–Q3), percent | 61.5 (58.2–64.4) | 60.2 (53.6–65.0) | 61.8 (55.0–66.3) |
| Small airway count, n (SD) | 186 (124–250) | 18 (17–19) | 17 (14–18) |
Definition of abbreviations: COPD = chronic obstructive pulmonary disease; GOLD = Global Initiative for Chronic Obstructive Lung Disease; MESA = Multi-Ethnic Study of Atherosclerosis; PRMfSAD = parametric response mapping of functional small airway disease; Q = quartile; SPIROMICS = Subpopulations and Intermediate Outcome Measures in COPD Study; ULN = upper limit of normal.
Excludes participants without valid measurement of genetic risk score for COPD susceptibility and/or valid measurements of lung function and structure.
*
In ever-smokers.
†
Prebronchodilator.